Literature DB >> 2695321

Plasma glucagon response to intravenous alanine in obese and non-obese subjects.

T Asano1, H Ninomiya, K Kan, T Yamamoto, M Okumura.   

Abstract

To investigate glucagon (IRG) and insulin (IRI) responses to alanine infusion in obesity and to assess the effect of body weight reduction with respect to hormonal balance, we compared six obese subjects with nine normal weight controls. None of the subjects were diabetic by OGTT criteria. Plasma IRI and IRG were measured following IV alanine at a rate of 0.1 g/kg over a period of 2 min. Our obese subjects had an increase in IRG response to alanine, which was due to decreased suppression of alpha-cell function due to insulin resistance. Weight reduction via calorie restriction reduced insulin demand, resulting in reduced plasma IRI by restoring beta-cell function, and the IRG response was paradoxically decreased as compared with that before weight loss. It is conceivable that improvements in insulin sensitivity after body weight reduction may re-establish the normalization of pancreatic beta-cell function and the insulin-induced inhibition of IRG secretion. Our obese subjects were characterized by decreased IRG secretion which was reflected in a change in body weight reduction.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2695321     DOI: 10.1507/endocrj1954.36.767

Source DB:  PubMed          Journal:  Endocrinol Jpn        ISSN: 0013-7219


  2 in total

1.  Impact of obesity severity and duration on pancreatic β- and α-cell dynamics in normoglycemic non-human primates.

Authors:  R Guardado-Mendoza; L Jimenez-Ceja; A Majluf-Cruz; S Kamath; T V Fiorentino; F Casiraghi; A O C Velazquez; R A DeFronzo; E Dick; A Davalli; F Folli
Journal:  Int J Obes (Lond)       Date:  2012-12-11       Impact factor: 5.551

2.  The Impact of Amino Acids on Postprandial Glucose and Insulin Kinetics in Humans: A Quantitative Overview.

Authors:  Bart van Sloun; Gijs H Goossens; Balazs Erdos; Michael Lenz; Natal van Riel; Ilja C W Arts
Journal:  Nutrients       Date:  2020-10-21       Impact factor: 5.717

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.